Peter Greenleaf
2013 - Histogenics
In 2013, Peter Greenleaf earned a total compensation of $456.5K as Former Director, President and Chief Executive Officer at Histogenics.
Compensation breakdown
| Option Awards | $230,967 |
|---|---|
| Salary | $196,575 |
| Other | $28,957 |
| Total | $456,499 |
Greenleaf received $231K in option awards, accounting for 51% of the total pay in 2013.
Greenleaf also received $196.6K in salary and $29K in other compensation.
Rankings
In 2013, Peter Greenleaf's compensation ranked 9,647th out of 12,286 executives tracked by ExecPay. In other words, Greenleaf earned more than 21.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,647 out of 12,286 | 22nd |
Division Manufacturing | 3,573 out of 4,612 | 23rd |
Major group Chemicals And Allied Products | 1,133 out of 1,466 | 23rd |
Industry group Drugs | 880 out of 1,160 | 24th |
Industry Biological Products, Except Diagnostic Substances | 152 out of 200 | 24th |
Source: SEC filing on April 28, 2015.
Greenleaf's colleagues
We found three more compensation records of executives who worked with Peter Greenleaf at Histogenics in 2013.
News
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2021 pay falls 88% to $1.2M
April 18, 2022
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2020 pay jumps 1,353% to $11M
May 10, 2021
Avalo Therapeutics Chairman Simon Pedder's 2019 pay jumps 13,562% to $3.8M
April 28, 2020
Avalo Therapeutics CEO Peter Greenleaf's 2018 pay jumps 17,372% to $5.1M
June 19, 2019